{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:38Z","timestamp":1794047498781,"version":"4.8.0"},"reference-count":13,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.287053","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:56:07Z","timestamp":1743652567000},"page":"2493-2497","source":"Crossref","is-referenced-by-count":2,"title":["A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma"],"prefix":"10.3324","volume":"110","author":[{"given":"Noa","family":"Biran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Zolotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Phull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeil","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Feinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palka","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Della","family":"Pia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"DeAgresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Biamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Rutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kumka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"80593","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma (Version 4.2024). 2024."},{"key":"80594","unstructured":"Surveillance Epidemiology End Results (SEER) Program Populations. National Cancer Institute, DCCPS, Surveillance Research Program. Released March. 1969-2022."},{"key":"80595","doi-asserted-by":"crossref","unstructured":"Argueta C, Kashyap T, Klebanov B. Selinexor synergizes with DEX to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget. 2018; 9(39):25529-25544.","DOI":"10.18632\/oncotarget.25368"},{"key":"80596","doi-asserted-by":"crossref","unstructured":"Tai YT, Landesman Y, Acharya C. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014; 28(1):155-165.","DOI":"10.1038\/leu.2013.115"},{"key":"80597","doi-asserted-by":"crossref","unstructured":"Kashyap T, Argueta C, Aboukameel A. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016; 7(48):78883-78895.","DOI":"10.18632\/oncotarget.12428"},{"key":"80598","doi-asserted-by":"crossref","unstructured":"Chari A, Vogl DT, Gavriatopoulou M. Oral selinexor-DEX for triple-class refractory multiple myeloma. N Engl J Med. 2019; 381(8):727-738.","DOI":"10.1056\/NEJMoa1903455"},{"key":"80599","doi-asserted-by":"crossref","unstructured":"Chen CI, Gutierrez M, Siegel DS. Selinexor demonstrates marked synergy with DEX (Sel-Dex) in preclinical models and in patients with heavily pretreated refractory multiple myeloma (MM). Blood. 2014; 124(21):4773-4773.","DOI":"10.1182\/blood.V124.21.4773.4773"},{"key":"80600","unstructured":"Bahils N, Chen C, Sebag M. A phase 1B\/2 study of selinexor in combination with backbone therapies for treatment of relapsed\/refractory multiple myeloma. 2024."},{"key":"80601","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"80602","unstructured":"R Core Team. 2022."},{"key":"80603","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"80604","doi-asserted-by":"crossref","unstructured":"Baljevic M, Gasparetto C, Schiller GJ. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem. 2022; 3(4):1270-1276.","DOI":"10.1002\/jha2.572"},{"key":"80605","doi-asserted-by":"crossref","unstructured":"Richard S, Chari A, Delimpasi S. Selinexor, bortezomib, and DEX versus bortezomib and DEX in previously treated multiple myeloma: outcomes by cytogenetic risk. Am J Hematol. 2021; 96(9):1220-1130.","DOI":"10.1002\/ajh.26261"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12009\/78273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12009\/78888","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12009\/78273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:30Z","timestamp":1794046110000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287053","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}